Head-to-head evidence
Acellbia vs CT-P10
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline
Acellbia
Developed by Biocad
NCT02744196 · Phase 3 · completed
This was a randomized, triple-blinded, placebo-controlled trial with 159 patients and a validated disease-response primary endpoint (ACR20). The result was clearly positive: 65.7% of Acellbia-treated patients achieved ACR20 at week 24 versus 29.4% on placebo (p<0.0001).
CT-P10
Developed by Celltrion
NCT02149121 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Acellbia's landscape · CT-P10's landscape